PMN חוב כולל להון ProMIS Neurosciences

ProMIS Neurosciences (PMN) is developing targeted antibodies against Alzheimer's disease, betting on massive deferred demand and high future returns. The business currently relies on clinical trial results and lacks a steady stream of income. This chart on GURU.Markets shows a total debt-to-equity ratio of 0.00, highlighting a capital shortage and a heavy dependence on R&D investments.

This ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the risk of dependence on creditors. The current value of 0.00 against the backdrop of antibody clinical trial costs confirms a restrained approach to borrowing, while the debt leverage history of ProMIS Neurosciences (PMN) demonstrates resilient reserves and strict control over R&D expenditures.